Quick Take
- Brainomix AI tripled stroke functional independence rates from 16% to 48% in UK study
- Over 50% increase in life-saving mechanical thrombectomy procedures where deployed
- Real-time brain scan processing delivers results to physicians within two minutes
- Platform now operational across UK and expanding into US healthcare systems
- Study covered largest real-world evaluation of stroke AI imaging technology
A groundbreaking AI platform is revolutionizing stroke emergency care across the UK, delivering recovery outcomes that could transform global healthcare delivery, according to comprehensive real-world evaluation data.
Brainomix’s AI-powered imaging technology has tripled the number of stroke patients achieving functional independence, with rates jumping from 16% to 48% in the Royal Berkshire Hospital study. The sophisticated platform processes brain scans in real-time, supporting clinicians across specialist and general hospitals with instant diagnostic insights.
AI Addresses Critical Time Factor in Emergency Stroke Care
Time equals brain tissue in stroke emergencies, with research showing patients lose approximately two million brain cells per minute during stroke onset. David Hargroves, NHS Clinical Director for Stroke, stressed this urgency: “AI decision support technology is revolutionizing how we help people affected by stroke. Quick diagnosis and treatment is critical, and AI provides real-time brain scan interpretation, supporting expert doctors to make faster treatment decisions.”
The technology fills a significant gap in stroke care delivery. Currently, only 25 of England’s 170 acute hospitals offer mechanical thrombectomy procedures. Most stroke patients arrive at local emergency departments, requiring rapid identification and transfer to specialist centers before irreversible brain damage occurs.
The largest real-world evaluation of stroke AI imaging showed mechanical thrombectomy procedures increased by over 50% where Brainomix software operates, demonstrating clear clinical impact across multiple healthcare settings.
Platform Demonstrates European Leadership with US Validation
Brainomix has established itself as Europe’s leading stroke AI platform, with widespread deployment across UK and European healthcare systems. The company’s success extends to US markets, where validation by world-class stroke institutions demonstrates similar clinical impact.
“Brainomix helps clinicians improve care delivery for stroke patients worldwide, validated by expanding published real-world evidence,” noted Dr. Michalis Papadakis, CEO and Co-Founder.
The Oxford Academic Health Science Network evaluation revealed participating hospitals achieved treatment rates 55% higher than national averages, reaching 5.7% compared to the 3.6% baseline. Some high-performing facilities exceeded 10% treatment rates, meeting NHS Long Term Plan targets.
Seamless Integration Creates Hospital Networks
Brainomix’s competitive advantage stems from seamless integration into existing healthcare infrastructure. The platform processes CT and MRI scans within two minutes, delivering results to physicians’ smartphones and hospital systems simultaneously. This connectivity creates networks between specialists at different hospitals, improving communication and care coordination.
After securing the NHS AI in Health and Care Award in 2020, Brainomix established partnerships with NHS England and The Health Innovation Network, creating sustainable market positioning with proven regulatory backing.
Healthcare AI Market Accelerates with Measurable Outcomes
Healthcare AI adoption accelerates as organizations seek measurable patient outcomes. Stroke treatment represents an ideal use case, combining time-sensitive decisions with clear success metrics. The technology reduces error margins while expediting treatment pathways, lowering long-term disability risks and associated care costs.
“Harnessing AI imaging technology within stroke networks has potential to transform outcomes for many more patients,” emphasized Professor Gary Ford CBE, Chief Executive of Oxford AHSN.
Global Healthcare Systems Monitor UK Success
International healthcare systems are closely monitoring UK’s AI deployment success. US stroke institutions validate similar Brainomix implementations, indicating cross-border scalability. Australia, Canada, and EU nations position themselves for comparable AI adoption, driven by demonstrated recovery improvements and cost efficiencies.
Regulatory frameworks evolve to accommodate AI healthcare solutions. The EU’s AI Act considerations and FDA approval pathways create standardized deployment routes for validated technologies like Brainomix 360 Stroke.
The global stroke AI market could reach $2.8 billion by 2027, growing at 15% annually, based on current adoption rates and NHS deployment scale. Early AI healthcare leaders like Brainomix position themselves to establish dominant market positions before competitors achieve comparable clinical validation.
